Felix Wagner 
Munich-based Proxima Fusion secured €411 million in a €2.5 billion valuation round led by XTX Ventures and East X Ventures, with Google as a notable investor. The funding will accelerate development of its nuclear fusion technology, including the Alpha stellarator project. The company aims to secure additional €1.2 billion from the German federal government for commercialization.
Porelio, a Germany-based deeptech startup developing advanced materials for industrial separation and water treatment, raised €2.4 million in a pre-seed round led by Faber. The funding will scale its patented continuous-flow manufacturing process for Functionalized Ordered Mesoporous Silicas (FOMS), which capture pollutants like PFAS and recover precious metals more efficiently than existing methods.
Andercore, a German startup, secured 30 million in funding as part of its latest financing round.
blue activity, a Heidelberg-based startup, is developing a solution to replace chemical biocides in industrial cooling systems with microorganisms. Founded by Lars Havighorst, the company aims to provide an eco-friendly alternative to traditional chemical treatments.
calltime founder Jonathan Kurth reveals the company has over 300 customers ranging from scale-ups to corporations and aims to double this number while increasing revenue per customer in the next year.
Ysios Capital, a leading European venture capital firm in life sciences, announced the divestment of Memo Therapeutics AG following its acquisition by global biopharmaceutical company Ipsen. The deal includes an initial payment of 200 million euros.
The German government approved JD.com’s acquisition of MediaMarktSaturn with conditions to safeguard customer data. The European Commission is reviewing the deal for potential antitrust issues related to alleged Chinese state subsidies.
Vienna-based AI startup Fonio, led by CEO Daniel Keinrath, raised $17 million in funding from 20VC after previously avoiding venture capital.
Epitome Therapeutics, an Austrian BioTech startup focused on precision epigenome editing, secured €4 million in pre-seed funding led by XISTA Science Ventures and Caesar Ventures. The funding includes €2 million in equity and €2 million in non-dilutive grants. The company aims to develop its CADENCE platform for programmable gene expression and advance its first drug candidate.
Heimstatt addresses depopulation in rural German towns by linking municipalities with young families seeking to relocate.